Ovarian Cancer Clinical Trial

A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy

Summary

The researchers are doing this study to look at the health outcomes of people with advanced ovarian cancer who have a second look laparoscopy (SLL) after they complete their first course of chemotherapy. The researchers will compare the health outcomes of people who have minimal residual disease (MRD-small amounts of cancer cells in the body after a person receives treatment) at the time of SLL with the health outcomes of people who do not have MRD at the time of SLL. The researchers are also doing this study to determine if SLL is safe and practical (feasible) in people with advanced ovarian cancer who have completed the first course of therapy for their disease.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients assigned female at birth≥ 18 years of age
Suspected or known stage III-IV epithelial ovarian cancer for which the patient has undergone, or is planned to undergo, attempted primary or interval debulking surgery

Homologous Recombination Deficiency testing should be planned to be completed prior to completion of initial platinum/taxane chemotherapy. HRD testing can be determined using :

Confirmation of deleterious Somatic or Germline BRCA mutation
CLIA certified test for HRD
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

Exclusion Criteria:

Patients with the inability to swallow oral medications or impaired gastrointestinal absorption due to gastrectomy or drainage gastrostomy tube
Patients receiving standard of care or investigational protocol directed treatment are eligible for this study, with the exception of protocol directed treatment which would prohibit the SLL surgery from being performed

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Estimated Enrollment:

80

Study ID:

NCT06240598

Recruitment Status:

Recruiting

Sponsor:

Memorial Sloan Kettering Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge New Jersey, 07920, United States More Info
Rachel Grisham, MD
Contact
646-888-4653
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown New Jersey, 07748, United States More Info
Rachel Grisham, MD
Contact
646-888-4653
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale New Jersey, 07645, United States More Info
Rachel Grisham, MD
Contact
646-888-4653
Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities)
Commack New York, 11725, United States More Info
Rachel Grisham, MD
Contact
646-888-4653
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison New York, 10604, United States More Info
Rachel Grisham, MD
Contact
646-888-4653
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States More Info
Rachel Grisham, MD
Contact
646-888-4653
Kara Long Roche, MD
Contact
212-639-7043
Rachel Grisham, MD
Principal Investigator
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale New York, 11553, United States More Info
Rachel Grisham, MD
Contact
646-888-4653

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Estimated Enrollment:

80

Study ID:

NCT06240598

Recruitment Status:

Recruiting

Sponsor:


Memorial Sloan Kettering Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.